Vincent Obstetrics and Gynecology Service, Division of Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
Oncology (Williston Park). 2011 Sep;25(10):928-34.
Two-thirds of women who are newly diagnosed with invasive epithelial ovarian cancer present with stage III or IV disease.The preferred initial treatment has traditionally consisted of primary surgical debulking followed by platinum-based chemotherapy. However, recent data suggesting comparable efficacy for neoadjuvant chemotherapy and interval debulking have challenged this conventional dogma. Most patients with advanced ovarian cancer will achieve remission regardless of initial treatment, but 80% to 90% of patients will ultimately relapse. The timing and clinical benefit of a second debulking operation for recurrent disease is even more contentious. This article focuses on the recent debate regarding when--or whether--patients with ovarian cancer should undergo aggressive surgical resection.
三分之二新诊断为浸润性上皮性卵巢癌的女性患者处于 III 期或 IV 期。传统上，首选的初始治疗方法是初始手术减瘤，然后进行铂类化疗。然而，最近的数据表明新辅助化疗和间隔减瘤具有相似的疗效，这对这一传统观念提出了挑战。大多数晚期卵巢癌患者无论初始治疗如何都会缓解，但 80%至 90%的患者最终会复发。对于复发性疾病再次进行减瘤手术的时间和临床获益更具争议性。本文重点讨论了最近关于卵巢癌患者何时（或是否）应进行积极手术切除的争论。
